By: IPP Bureau
Last updated : November 12, 2025 11:08 am
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
J B Chemicals and Pharmaceuticals reported strong Q2 FY26 results with consolidated revenue up 16% to Rs. 1,040 crore and net profit rising 19 per cent to Rs. 208 crore. Half-year revenue grew to Rs. 2,008 crore with net profit at Rs. 410 crore.
The Competition Commission of India approved Torrent Pharmaceuticals' acquisition of J B Chemicals on October 21, 2025, with Torrent set to issue 51 equity shares for every 100 J B Chemicals shares. The company also allotted 9.19 lakh equity shares under its ESOS, increasing paid-up capital to Rs. 15.66 crore.
Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated “JB’s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands — including recently acquired portfolios — continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year.
Over the years, JB has consistently delivered strong revenue and margin performance. We are confident in sustaining this positive momentum as we progress toward our operational and strategic goals for the current year and beyond. As we chart the path ahead, our focus remains on building a progressive, agile, and future-ready organization.”